Accelerating Drug Development through Repurposed FDA-Approved Drugs for COVID-19: Speed Is Important, Not Haste

作者
James T. Gordy,Kaushiki Mazumdar,Noton K. Dutta
出处
期刊:Antimicrobial Agents and Chemotherapy [American Society for Microbiology]
卷期号:64 (8) 被引量:4
标识
DOI:10.1128/aac.00857-20
摘要

A life-threatening, emerging respiratory disease, called coronavirus disease 2019 (COVID-19), originated in the city of Wuhan in China's Hubei province in December 2019 and has been classified as an international pandemic by the World Health Organization.As of 30 April 2020, more than 3,249,022 COVID-19 cases caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) have been recorded worldwide, and more than 230,804 people have been reported dead.Upon this outbreak, global collaborations between the public, private, and academic sectors have been coordinated, and as a result of these extraordinary endeavors, SARS-CoV-2 has been identified and characterized (1, 2).Work continues across the globe to further characterize this virus and the disease it potentiates.For instance, the crystal structure of the SARS-CoV-2 nucleocapsid protein (N) has been determined to be similar to that of the previously described coronavirus N proteins, albeit with distinct surface electrostatic potential characteristics (3).Additionally, emerging novel clinical and basic research data via molecular modeling (MD), docking, and MD simulation-based approaches can be the starting point for generating hypotheses, as it was for Jin et al. in their preprint analysis of the M pro SARS-CoV-2 enzyme (4).Studies such as that one can effectively guide further targeted bench work to accelerate the development of specific drugs to treat SARS-CoV-2.However, these specifically targeted antiviral therapies will take several years to develop and evaluate; therefore, to date, quarantine and transmission-blocking measures are the only operational treatments for both SARS-CoV strains.Social interventions such as these are efficacious at the population level, but they are not socially or economically sustainable in the long term, and they do not help those who contract the disease (5).In the short term, a range of existing FDA-approved drugs potentially could be repurposed to treat COVID-19 relatively quickly.Recent publications have drawn attention to the possible benefit of antimalarial drugs atovaquone (6), chloroquine (7, 8), and hydroxychloroquine (9, 10); the angiotensin-converting enzyme inhibitor moexipril (6); the cholesterol-lowering rosuvastatin (11); the chemotherapy drugs daunorubicin and mitoxantrone (6); the painkillers baricitinib (12), thalidomide (ClinicalTrials-.govregistration no.NCT04273581), metamizole, and nafamostat mesylate (13); the antihistamine bepotastine; the antidiabetic agent metformin; the antischizophrenia drug haloperidol; the interleukin-6 (IL-6) inhibitor sarilumab; and the IL-6 receptor blocker tocilizumab (ClinicalTrials.govregistration no.NCT04322773).Several antiviral drugs are also being tested, including antrafenine ( 14), darunavir (6, 15), elbasvir (14), favipiravir (15), ledipasvir ( 14), lopinavir/ritonavir (15), nelfinavir (6), paritaprevir (14), remdesivir (8, 15, 16), ribavirin (17), telbivudine saquinavir (6), umifenovir (15), and

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
摩纳哥第一深情完成签到,获得积分10
2秒前
子虚一尘完成签到,获得积分10
2秒前
桐桐的应助被李68采纳,获得10
2秒前
2秒前
3秒前
Oliver完成签到,获得积分10
3秒前
zyy完成签到,获得积分10
3秒前
6秒前
王炜德完成签到,获得积分10
8秒前
大知闲闲发布了新的文献求助10
8秒前
ye发布了新的文献求助10
9秒前
风吹麦浪发布了新的文献求助10
9秒前
gsz发布了新的文献求助10
9秒前
许迪完成签到,获得积分10
9秒前
9秒前
10秒前
四字完成签到,获得积分10
10秒前
NiuNiu4完成签到,获得积分10
10秒前
11秒前
11秒前
ranrika完成签到,获得积分10
11秒前
无花果的应助被ddd采纳,获得10
12秒前
12秒前
王悦完成签到,获得积分10
12秒前
13秒前
13秒前
13秒前
余谏己完成签到 ,获得积分10
14秒前
深情安青的应助被科研通管家采纳,获得10
14秒前
天天向上的应助被科研通管家采纳,获得30
14秒前
14秒前
Jasper的应助被科研通管家采纳,获得30
14秒前
上官若男的应助被科研通管家采纳,获得10
14秒前
赘婿的应助被科研通管家采纳,获得10
14秒前
Akim的应助被pinguin采纳,获得10
14秒前
JamesPei的应助被科研通管家采纳,获得10
14秒前
DW的应助被科研通管家采纳,获得10
14秒前
研友_VZG7GZ的应助被科研通管家采纳,获得10
15秒前
leecopper001发布了新的文献求助10
15秒前
搜集达人的应助被科研通管家采纳,获得10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8186676
求助须知:如何正确求助?哪些是违规求助? 9574945
关于积分的说明 21839037
捐赠科研通 7784275
什么是DOI,文献DOI怎么找? 3434808
关于科研通互助平台的介绍 2559187
邀请新用户注册赠送积分活动 2481611